gastrinoma


Also found in: Medical, Wikipedia.
Related to gastrinoma: vipoma
Translations

gastrinoma

n gastrinoma m
References in periodicals archive ?
Another patient with the metastatic gastrinoma NET exhibited six months stable disease, and two patients with metastatic non-small cell lung cancer exhibited four months stable disease.
Research suggests that gastrinoma (carcinoid tumor) diagnosis is delayed by PPI suppression of symptoms.
Study of a primary gastrinoma in the common hepatic duct--a case report.
Indium-111 has the following uses: labeled oxine for inflammatory disease detection, labeled monoclonal antibodies for colorectal, ovarian, and prostate cancer detection, peptide receptor imaging for carcinoid, insulinoma, gastrinoma, pheochromocytoma, medullary thyroid carcinoma, small cell carcinoma of lung, and pituitary adenoma detection.
ChiRhoStim is approved for Pancreatic Function Testing, facilitating cannulation during ERCP, and Gastrinoma Testing.
Pancreatic neuroendocrine tumors Tumor Prevalence Malignancy Rate amongst PETs Insulinoma 40% 10% Gastrinoma 20% 60% Non-Functioning 35% 85% Glucagonoma Rare 80% VIPoma Rare 70% Somatistatinoma Rare 70% Tumor Clinical Symptoms, Features Insulinoma Hypoglycemia, elevated serum C-peptide Gastrinoma Gastric hypersecretion leading to post/bulbar ulcers and diarrhea.
4) The most common subtype is the gastrin-secreting NET, or gastrinoma, associated with Zollinger-Ellison syndrome in one-third of cases.
Neuroendocrine tumors, produce excessive amounts of hormones and include carcinoid syndrome, Zollinger Ellison syndrome, VIPomas, insulinomas gastrinoma, glucaginoma and somatostatinoma, among others.
These tumors are classified according to the predominant hormone of oversecretion: insulinoma, gastrinoma, vasoactive intestinal peptide-secreting tumors (VIPoma), glucagonoma, somatostatinoma, and growth-hormone-releasing factor-secreting tumors (GRFomas).
The observation that the increase in CgA(340[right arrow]) immunoreactivity after trypsination of plasma samples was significantly higher in plasma from patients with very extensive gastrointestinal neuroendocrine tumors (group 3) than in plasma from the patients with extensive (group 2) and local disease (group 1) (Table 2) is in agreement with earlier reports (5, 8) in which a lower degree of processing of progastrin was found in plasma from gastrinoma patients with metastases.